Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.41 |
| ▸ | CFTR | P13569 | 2/20 | 0.39 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.39 |
| ▸ | TUBB | P07437 | 2/20 | 0.39 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.39 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.39 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.39 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.39 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.39 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.39 |
| ▸ | TUBB8 | Q3ZCM7 | 2/20 | 0.39 |
| ▸ | TUBA3E | Q6PEY2 | 2/20 | 0.39 |
| ▸ | TUBA1A | Q71U36 | 2/20 | 0.39 |
| ▸ | TUBA1C | Q9BQE3 | 2/20 | 0.39 |
| ▸ | TUBB6 | Q9BUF5 | 2/20 | 0.39 |
| ▸ | TUBB2B | Q9BVA1 | 2/20 | 0.39 |
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 4/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2475020 | 0.85 | KDM4E (0.38) | KDM4ECFTRTUBB4ATUBBTUBA3C | |
| SCHEMBL2478036 | 0.83 | CFTR (0.36) | KDM4ECFTRTUBB4ATUBBTUBA3C | |
| SCHEMBL12201211 | 0.82 | KDM4E (0.43) | KDM4ECFTRTUBB4ATUBBTUBA3C | |
| SCHEMBL11888132 | 0.81 | ALDH1A1 (0.42) | KDM4ECFTRHPGDSMN1; SMN2CYP1A2 | |
| SCHEMBL4766005 | 0.78 | TUBB4A (0.39) | KDM4ECFTRTUBB4ATUBBTUBA3C | |
| SCHEMBL1506478 | 0.72 | NLRP3 (0.41) | KDM4ETUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL2475128 | 0.72 | CFTR (0.70) | KDM4ECFTRHPGDALDH1A1NOTUM | |
| SCHEMBL2389464 | 0.71 | CFTR (0.43) | KDM4ECFTRHPGDSMN1; SMN2CYP1A2 | |
| SCHEMBL14015061 | 0.71 | KDM4E (0.49) | KDM4ETUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL3532988 | 0.71 | HPGD (0.42) | KDM4ETUBB4ATUBBTUBA3CTUBA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2479175-A1 | Compounds and methods for treating dyslipidemia | Eli Lilly and Company (US) | 2012-07-25 | — | — | EP | disclosed |
| EP-1761522-B1 | COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA | LILLY CO ELI (US) | 2011-10-12 | — | — | EP | disclosed |
| EP-1761522-B1 | COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA | LILLY CO ELI (US) | 2011-10-12 | — | — | EP | disclosed |
| US-7786108-B2 | Compounds and method for treating dyslipidemia | ELI LILLY AND COMPANY (US) | 2010-08-31 | — | — | US | disclosed |
| US-7786108-B2 | Compounds and method for treating dyslipidemia | ELI LILLY AND COMPANY (US) | 2010-08-31 | — | — | US | disclosed |
| US-7786108-B2 | Compounds and method for treating dyslipidemia | ELI LILLY AND COMPANY (US) | 2010-08-31 | — | — | US | disclosed |
| US-20100204207-A1 | Compounds and Methods for Treating Dyslipidemia | CHEN XINCHAO | 2010-08-12 | — | — | US | disclosed |
| US-20100204207-A1 | Compounds and Methods for Treating Dyslipidemia | CHEN XINCHAO | 2010-08-12 | — | — | US | disclosed |
| US-20100204207-A1 | Compounds and Methods for Treating Dyslipidemia | CHEN XINCHAO | 2010-08-12 | — | — | US | disclosed |
| US-20070244095-A1 | S)-(3,5-Bistrifluoromethylbenzyl)-(1-cyclopentylmethyl-7-methyl-8-trifluoromethyl-2,3,4,5-tetrahydro-1H-benzo[b]azepin-5-yl)-(2-methyl-2H-tetrazol-5-yl)amine, for treating and/or preventing diseases related to abnormal cholesterol ester transfer protein activity such as atherosclerosis | ELI LILLY AND COMPANY | 2007-10-18 | — | — | US | disclosed |
| US-20070244095-A1 | S)-(3,5-Bistrifluoromethylbenzyl)-(1-cyclopentylmethyl-7-methyl-8-trifluoromethyl-2,3,4,5-tetrahydro-1H-benzo[b]azepin-5-yl)-(2-methyl-2H-tetrazol-5-yl)amine, for treating and/or preventing diseases related to abnormal cholesterol ester transfer protein activity such as atherosclerosis | ELI LILLY AND COMPANY | 2007-10-18 | — | — | US | disclosed |
| US-20070244095-A1 | S)-(3,5-Bistrifluoromethylbenzyl)-(1-cyclopentylmethyl-7-methyl-8-trifluoromethyl-2,3,4,5-tetrahydro-1H-benzo[b]azepin-5-yl)-(2-methyl-2H-tetrazol-5-yl)amine, for treating and/or preventing diseases related to abnormal cholesterol ester transfer protein activity such as atherosclerosis | ELI LILLY AND COMPANY | 2007-10-18 | — | — | US | disclosed |
| EP-1761522-A1 | COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA | ELI LILLY AND COMPANY (US) | 2007-03-14 | — | — | EP | disclosed |
| WO-2006002342-A1 | COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA | ELI LILLY AND COMPANY (US) | 2006-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244095-A1 | S)-(3,5-Bistrifluoromethylbenzyl)-(1-cyclopentylmethyl-7-methyl-8-trifluoromethyl-2,3,4,5-tetrahydro-1H-benzo[b]azepin-5-yl)-(2-methyl-2H-tetrazol-5-yl)amine, for treating and/or preventing diseases related to abnormal cholesterol ester transfer protein activity such as atherosclerosis | CETP, APOB, MTTP | KDM4E 959/4885CFTR 716/4885TUBB4A 2191/4885 |
| US-20100204207-A1 | Compounds and Methods for Treating Dyslipidemia | APOB, LIPC, PCSK9 | KDM4E 2226/4885CFTR 1010/4885TUBB4A 1861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.